- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | What Analysts Are Saying About TScan Therapeutics Stock | 3 | Benzinga.com | ||
| 07.05. | H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating | 1 | Investing.com | ||
| 06.05. | TScan Therapeutics GAAP EPS of $0.26 | 3 | Seeking Alpha | ||
| 06.05. | TScan Therapeutics May 2025 slides: advancing TCR-T therapies with positive Phase 1 data | 1 | Investing.com | ||
| 06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.04. | Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts | 1 | Benzinga.com | ||
| 27.03. | TScan Therapeutics, Inc.: TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access | 2 | GlobeNewswire (USA) | ||
| 06.03. | Breaking Down TScan Therapeutics: 4 Analysts Share Their Views | 1 | Benzinga.com | ||
| 05.03. | TScan Therapeutics files for $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M | 1 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 05.03. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.12.24 | Why Is TScan Therapeutics Stock Gaining Today? | 3 | Benzinga.com | ||
| 26.12.24 | TScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% Premium | - | RTTNews | ||
| 26.12.24 | TScan Therapeutics announces ~$30M direct offering | 1 | Seeking Alpha | ||
| 26.12.24 | TScan sichert sich 30 Millionen US-Dollar durch Optionsscheinverkauf an Lynx1 | 4 | Investing.com Deutsch | ||
| 26.12.24 | TScan secures $30 million through warrant sale to Lynx1 | 1 | Investing.com |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,05 | +0,79 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| MEDIGENE | 0,120 | +2,13 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| AMGEN | 240,05 | +2,24 % | Aktienmarkt: Kurs der Amgen-Aktie im Minus (234,3972 €) | Im US-amerikanischen Wertpapierhandel notiert die Amgen-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 262,26 US-Dollar. Für Inhaber von Amgen ist der heutige Handelstag... ► Artikel lesen | |
| BIOFRONTERA | 2,650 | 0,00 % | Biofrontera verlängert Ameluz-Patent für Aknebehandlung bis 2043 | ||
| BIOGEN | 109,30 | +1,34 % | Goldman Sachs maintains Biogen buy rating, $196 target | ||
| REGENERON PHARMACEUTICALS | 520,40 | +1,64 % | Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock | ||
| EDITAS MEDICINE | 1,277 | +3,69 % | Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting | Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia... ► Artikel lesen | |
| GALAPAGOS NV | 23,900 | -0,42 % | Galapagos NV: Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 | Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation... ► Artikel lesen | |
| IMMATICS | 4,136 | +1,17 % | Immatics Announces First Quarter 2025 Financial Results and Business Update | IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b... ► Artikel lesen | |
| AYALA PHARMACEUTICALS | 0,010 | 0,00 % | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,100 | +0,92 % | Autolus Therapeutics plc: Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress | ||
| IGM BIOSCIENCES | 1,000 | +1,52 % | IGM Biosciences, Inc. - 10-Q, Quarterly Report | ||
| ONCOPEPTIDES | 0,178 | +1,37 % | Oncopeptides AB: Oncopeptides publishes Q1 report 2025 | Stockholm - May 15, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2025.
"The first... ► Artikel lesen | |
| AVACTA | 0,390 | +1,56 % | Avacta Group PLC - Notice of Results | ||
| DERMATA THERAPEUTICS | 0,760 | -1,31 % | Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | - Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -- Dermata entered into a Clinical... ► Artikel lesen |
TSCAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,250 Euro und damit -2,34 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.